ARTHEx Biotech Revenue and Competitors
Estimated Revenue & Valuation
- ARTHEx Biotech's estimated annual revenue is currently $5.3M per year.
- ARTHEx Biotech's estimated revenue per employee is $155,000
Employee Data
- ARTHEx Biotech has 34 Employees.
- ARTHEx Biotech grew their employee count by 55% last year.
ARTHEx Biotech's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Co-founder | Reveal Email/Phone |
2 | Head Preclinical Toxicology | Reveal Email/Phone |
3 | Financial & HR Manager | Reveal Email/Phone |
4 | QA Manager | Reveal Email/Phone |
5 | Research Assistant | Reveal Email/Phone |
6 | Research And Development Scientist | Reveal Email/Phone |
ARTHEx Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.4M | 41 | N/A | N/A | N/A |
#2 | $0.9M | 6 | N/A | N/A | N/A |
#3 | $5.9M | 38 | N/A | N/A | N/A |
#4 | $47M | 303 | 18% | N/A | N/A |
#5 | $9.5M | 61 | 11% | N/A | N/A |
#6 | $46.7M | 301 | 25% | N/A | N/A |
#7 | $1.7M | 11 | -8% | N/A | N/A |
#8 | $3.7M | 24 | -11% | N/A | N/A |
#9 | $4.2M | 27 | 13% | N/A | N/A |
#10 | $5.3M | 34 | 6% | N/A | N/A |
What Is ARTHEx Biotech?
ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. \n \nARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role.\n\nThe first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis.\n\nTo learn more about Arthex Biotech, please visit us at www.arthexbiotech.com
keywords:N/A
N/A
Total Funding
34
Number of Employees
$5.3M
Revenue (est)
55%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Paterna
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 53 | 56% | N/A |
#2 | $7.1M | 56 | 0% | N/A |
#3 | N/A | 57 | 14% | N/A |
#4 | $26.7M | 82 | 3% | N/A |
#5 | N/A | 87 | 26% | N/A |